Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01074047 · ClinicalTrials.gov registry record · Phase 3
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
A Phase 3 study of Acute Myeloid Leukemia, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 488
- Enrollment target
- 20
- Study locations
NCT01074047 is a Phase 3 study of Acute Myeloid Leukemia that has completed, run by Celgene. The registered enrollment target is 488 participants, above the 114-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (328% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT01074047, a Phase 3 study of Acute Myeloid Leukemia, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 488 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the effect of azacitidine (Vidaza) to conventional care regimens on overall survival in elderly AML patients.
Conditions Studied
Interventions
- DRUG Azacitidine
- DRUG Conventional Care Regimen
Study Locations (20)
Victoria
- Peter MacCallum Cancer Centre - East Melbourne
- Western Hospital - Footscray
- Royal Melbourne Hospital - Melbourne
Other
- St Vincent's Hospital - Fitzroy
- Landeskliniken Salzburg Saint Johanns-Spital, III Medizinische Abteilung - Salzburg
- Centre Hospitalier de Jolimont-Lobbes - La Louvière
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- MD Anderson Cancer Center - Houston
New South Wales
- Prince of Wales Hospital - Randwick
South Australia
- Royal Adelaide Hospital - Adelaide
Upper Austria
- Klinikum Wels-Grieskirchen GmbH - Wels
Vienna
- Wilhelminenspital, I Medizinische Abt. - Vienna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 488 participants |
| Start Date | 2010-06-01 |
| Est. Completion | 2016-07-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01074047
The ClinicalTrials.gov registry entry for NCT01074047 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 488 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 114-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (328% higher). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Azacitidine is the first listed.
NCT01074047 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Victoria, Other, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01074047 about?
NCT01074047 is a clinical study titled "Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)". The purpose of this study is to compare the effect of azacitidine (Vidaza) to conventional care regimens on overall survival in elderly AML patients.
What is the current status of trial NCT01074047?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 488 participants. The study started on 2010-06-01. Estimated completion is 2016-07-25.
What conditions does trial NCT01074047 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia.
What interventions are being tested in trial NCT01074047?
The interventions under investigation include: Azacitidine (DRUG), Conventional Care Regimen (DRUG).
Who is sponsoring clinical trial NCT01074047?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01074047 being conducted?
This trial has 20 study locations across Massachusetts, Texas, New South Wales, South Australia, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RECRUITING · Phase 3
-
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RECRUITING · Phase 3
-
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
ACTIVE NOT RECRUITING · Phase 3
-
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 3
-
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.